Study of an NJ COVID vaccine factory
Eli Lilly slapped with DoJ subpoena over COVID-19 drug factory: Reuters
Eli Lilly and Co (NYSE: LLY) has received a subpoena from the US Department of Justice regarding its plant in New Jersey that manufactures its COVID-19 treatment, bamlanivimab, reports Reuters. The summons requested certain documents relating to its Branchburg, New Jersey site. He did not specify the documents requested by the summons. Earlier this month, company employees accused a factory executive of amending documents required by government regulators to minimize serious quality control issues at the Branchburg site. Eli Lilly is also under pressure due to quality control, production and regulatory issues at its Indianapolis plant, which bottles bamlanivimab, among other drugs. Price Action: LLY shares are down 1.58% to $ 197.82 during the market session on the last check Thursday. See more BenzingaClick here for options trades from BenzingaEli Lilly Mirikizumab improves fatigue in patients with Crohn’s disease Tirzepatide not inferior to titrated insulin glargine in patients with type 2 diabetes © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.